Efficacy and safety of oral semaglutide 25 mg once daily in adults with overweight or obesity (OASIS 4) - OASIS 4

ovo Nordisk A/S0 个研究点目标入组 300 人开始时间: 2022年8月12日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•1.Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study
•2.Male or female, age greater than or equal to 18 years at the time of signing informed consent.
•3.Body mass index (BMI) of
•a)Greater than or equal to 27.0 kg/m^2 with the presence of at least one of the following weight-related complications (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular (CV) disease
•b)Greater than or equal to 30.0 kg/m^2.
•4. History of at least one self-reported unsuccessful dietary effort to lose body weight
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 250
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 50

•1.A self-reported change in body weight greater than 5 kg within 90 days before screening irrespective of medical records
•2.HbA1c greater than or equal to 6.5% (48 mmol/mol) as measured by the central laboratory at screening

发起方